MAGENTIQ EYE Secures Series A Investment Led by aMoon to Drive the Future of AI-Powered Gastroenterology

Financing will certainly Assistance Commercialization in the U.S.A. and Europe, in addition to Ongoing Growth of MAGENTIQ COLO’s Advanced AI Capabilities

MAGENTIQ EYE LTD., a leading pioneer in AI-powered gastroenterology decision-support software program, today introduced the effective conclusion of its Collection A financing round.

MAGENTIQ EYE’s FDA- and CE-approved software program, MAGENTIQ-COLO, improves polyp discovery and evaluation capacities throughout colonoscopies, substantially enhancing adenoma discovery prices. MAGENTIQ-COLO likewise uses real-time understandings, and its CE-approved variation consists of polyp-size classification and kind evaluation, and progressed AI-generated records.

The round was led by aMoon, Israel’s biggest HealthTech devoted mutual fund, signed up with by interior financiers Norgine Ventures BV ( Netherlands), Nina Funding (EU & U.S.A.) and Namarel Ventures SL ( Spain), Nova Funding ( Italy), and personal financiers Benefit Bosch and Roon Doornink ( U.S.A.). Along with aMoon’s financial investment, companion Roy Wiesner will certainly sign up with the board of supervisors of MAGENTIQ EYE, bringing tactical understanding, worldwide point of view, and deep experience in structure effective wellness technology firms.

” This financial investment round notes a significant turning point for MAGENTIQ EYE. We are enjoyed invite aMoon and Roy Wiesner to our trip,” claimed Dror Zur, Ph.D., Creator and Chief Executive Officer at MAGENTIQ EYE. “With aMoon’s assistance, we will certainly speed up development and market accessibility, fulfilling the expanding need showed in our durable pipe of test and acquisition demands throughout the united state and Europe, and bring our innovative analysis devices to extra medical professionals and individuals worldwide.”

” We are pleased to companion with MAGENTIQ EYE, a firm leading the fee in AI-powered colonoscopy,” claimed Wiesner. “MAGENTIQ’s remedy attracts attention as one of the most exact out there, with the widest collection of attributes, cost-efficient scalability, and system versatility throughout GI and laparoscopic applications. We’re likewise urged by the solid very early industrial grip and the expanding passion from significant tactical gamers aiming to team up. This financial investment shows aMoon’s dedication to backing transformative wellness technology remedies that can drastically boost person results worldwide.”

The business remains in professional tests for analysis devices targeting customized illness in the reduced and top stomach system, such as ulcerative colitis, very early dysplasia in Barrett’s esophagus, and stomach digestive metaplasia, and is establishing automated top quality indications for GI treatments. Profits from the financing round will certainly sustain the ongoing advancement and development of these capacities, along with driving industrial development in the U.S.A., Europe, and around the world via straight sales and MAGENTIQ EYE’s existing and brand-new collaborations with sector leaders.

Regarding MAGENTIQ-EYE Ltd.

Established In 2014, MAGENTIQ-EYE offers a groundbreaking AI-aided colonoscopy remedy that uses among the very best efficiencies understood today. With around the world acknowledgment from the gastroenterology neighborhood, and lots of treatments done everyday with the help of MAGENTIQ-COLO, we are establishing the brand-new criterion of colonoscopy and conserving increasingly more lives.

Regarding aMoon

aMoon is an international Healthtech & Life Sciences VC fund headquartered in Israel with $ 1.3 B AUM. We companion with business owners using groundbreaking scientific research and modern technology to change health care and aid individuals live far better, much healthier lives. Backed by a group of researchers, medical professionals, and business owners, and an international network of financiers and sector leaders, we link profile firms to worldwide technology, financing, and clinical research study centers. Our Speed Fund spends from endeavor development via Collection A, while our Development Fund sustains later-stage firms in development, pre-IPO, or critical professional rounds.

Initially introduced July 30th, 2025